CiRA, Kyoto University and Astellas Phase 2 research agreement signed for iPS Cells
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
To enable company to be future-ready by tapping potential in CDMO space
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Subscribe To Our Newsletter & Stay Updated